Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1 Unknown 108 enrolled Qilu Pharmaceutical Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer

Timeline

Start: 2023-08-31
Primary completion: 2025-08-31
Completion: 2026-01-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QLH12016	Other / unclassified	—	—

Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Summary

Timeline

Drugs

Indications